DNA changes in healthy bladder provide clues on how cancer arises
The research reveals a huge diversity in the number and types of changes between individuals, indicating that a wide range of factors influence how bladder cancer develops
The first comprehensive study of DNA changes in healthy and diseased human bladder tissue has revealed that ‘cancer-driving’ mutations are common in healthy bladder tissue. The study, conducted by scientists at the Wellcome Sanger Institute, the University of Cambridge and their collaborators, provides an unprecedented view of the first steps towards bladder cancer.
Published today (1 October 2020) in Science, the research uncovered high variation in the number and types of changes between individuals, indicating that a wide range of factors influence how bladder cancer develops. The researchers also provided new insights into the link between smoking and bladder cancer, whereby bladder tissue is exposed to tobacco chemicals present in urine.
More than 10,000 people are diagnosed with bladder cancer every year in the UK, with around 5,000 deaths. Around 60 per cent of new cases occur in people aged 75 and over. Around half of bladder cancer cases are estimated to be preventable. Early diagnosis is also crucial, with 95 per cent of those diagnosed early surviving for one year or more, dropping to 36 per cent for late stage diagnosis*.
Cancers occur due to changes in DNA, known as somatic mutations, which continuously occur in all of our cells throughout life. Some somatic mutations, particularly those affecting known ‘cancer genes’, confer a competitive advantage that allows these mutated cells to expand more rapidly than normal cells and can lead to disease.
Technological developments have enabled the detection of somatic mutations linked to cancer in normal tissues, providing insights into the earliest stages of cancer and raising the prospect of early detection and treatment strategies**.
This new study used DNA sequencing to better understand the genetic changes in healthy and diseased bladder tissue. Clinicians from the University of Cambridge provided donated bladder tissue from five people with bladder cancer and 15 people with no history of cancer.
Researchers at the Wellcome Sanger Institute then took 2,097 biopsies from the tissue samples, using a technique called laser-capture microscopy to isolate segments of just a few hundred cells. DNA from these samples was genome sequenced and the sequences were analysed to characterise the landscape of somatic mutations.
The team found an unexpectedly high variability in the number and types of mutations and in the frequency of ‘cancer-driving’ mutations between individuals, suggesting that a wide range of factors affect the accumulation of mutations in the bladder. Some of these factors could be identified by their ‘mutational signature’ – tell-tale patterns of mutation in the genome caused by a certain chemical or process.
The study identified a new mutational signature associated with smoking, shedding light on why tobacco is the single greatest risk associated with bladder cancer. Though the bladder does not come into contact with smoke directly, the chemicals in tobacco products are filtered out of the body by the kidneys and come into contact with the bladder in the urine.
“One of the questions we sought to answer with this study was why bladder cancers have some of the highest mutation rates and cancer-driving mutations of any cancer type, even though the cells in the bladder divide slowly, reducing the chance of a genetic error. The high patient-to-patient variation in which genes were mutated and in the types of mutations may be consistent with the wide variety of factors that can contribute to bladder cancer. Further studies on the causes behind this variation could help uncover hidden causes of bladder cancer.”
Andrew Lawson, first author of the study from the Wellcome Sanger Institute
The researchers were surprised to find that mutations in key cancer genes such as TP53, FGFR3 and TERT were largely absent from healthy bladder tissue, despite the high number of mutations overall. As mutations in these genes are common in bladder tumours, their presence is a strong indicator that disease has set in.
“Like many cancers, early diagnosis of bladder cancer gives the patient a much greater chance of survival. The presence of mutations in key cancer genes in bladder tumours that are usually absent in normal tissue opens up the possibility of looking for these changes in fragments of DNA that are present in urine. These ‘liquid biopsies’ could be a non-invasive way to screen for bladder cancer earlier, which could help reduce the number of people who die from this disease.”
Thomas Mitchell, a senior author of the study from Cambridge University Hospitals and the Wellcome Sanger Institute
“This study reveals an unexpectedly rich landscape of mutation and selection in normal bladder, with large differences across individuals driven to some extent by our daily exposures. Thanks to technical advances, our understanding of how our cells mutate, compete and evolve as we age has been transformed over the last few years. In addition to shedding light on the origins of cancer and informing early detection efforts, these observations raise questions about the possible role of these widespread mutations in ageing and other diseases.”
Dr Inigo Martincorena, lead author of the study from the Wellcome Sanger Institute
If you need help or have any queries, please contact us.
Notes to Editors
*For more information on bladder cancer is available from Cancer Research UK (CRUK): https://www.cancerresearchuk.org/about-cancer/bladder-cancer/about
** Further information about these studies is available here: https://www.sanger.ac.uk/news_item/mutant-cells-colonise-our-tissues-over-our-lifetime/
Andrew R. J. Lawson, Federico Abascal and Tim H. H. Coorens et al. (2020). Extensive heterogeneity in somatic mutation and selection in the human bladder. Science. DOI: https://doi.org/10.1126/science.aba8347
This study was funded by Cancer Research UK (CRUK) and Wellcome.
- Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
- Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no funding from the UK government for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.
The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. To date, 107 affiliates of the University have won the Nobel Prize.
Founded in 1209, the University comprises 31 autonomous Colleges, which admit undergraduates and provide small-group tuition, and 150 departments, faculties and institutions. Cambridge is a global university. Its 19,000 student body includes 3,700 international students from 120 countries. Cambridge researchers collaborate with colleagues worldwide, and the University has established larger-scale partnerships in Asia, Africa and America.
The University sits at the heart of the ‘Cambridge cluster’, which employs 60,000 people and has in excess of £12 billion in turnover generated annually by the 4,700 knowledge-intensive firms in and around the city. The city publishes 341 patents per 100,000 residents. www.cam.ac.uk
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.
Related blog posts
24 Jan 2014
Understanding the origins of cancer
24.01.14: What makes that first cell mutate, leading to a life-threatening tumour? Ludmil Alexandrov explains how large-scale studies are ...
19 Nov 2020
COG-UK computing effort wins collaboration award for COVID-19 work
HPCwire award recognises consortium's sequencing of tens of thousands of viral genomes
16 Nov 2020
Wellcome Sanger Institute and COG-UK receive £12.2M UK Government investment for COVID-19 real-time genomic surveillance system
Institute researchers will support the COVID-19 Genomics UK consortium's work by providing high-throughput virus genome sequencing, creating surveillance software to ...